Literature DB >> 19151898

Genetic etiologies for phenotypic diversity in sickle cell anemia.

Martin H Steinberg1.   

Abstract

The clinical course of patients with sickle cell anemia, a Mendelian trait, is characteristically highly variable. HbF concentration and the presence of á thalassemia are established modulators of the disease, but cannot account for all of its clinical heterogeneity. To find additional genetic modulators of disease, genotype-phenotype association studies, where single nucleotide polymorphisms (SNPs) in candidate genes are linked with a particular phenotype, have been informative. SNPs in several genes of the TGF-beta/BMP superfamily, and some other genes linked to the endothelial function, and nitric oxide biology are associated with the subphenotypes of stroke, osteonecrosis, priapism, leg ulcers, pulmonary hypertension, and a more general measure of overall disease severity. Genome-wide association studies should help to confirm these observations and also to find hitherto unsuspected genetic modulators. Genetic association studies can have immediate prognostic value; they might also help to identify new pathophysiological pathways that could be susceptible to modulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151898      PMCID: PMC5823205          DOI: 10.1100/tsw.2009.10

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  62 in total

1.  Fetal hemoglobin levels in African American and Hispanic children with sickle cell disease at baseline and in response to hydroxyurea.

Authors:  Katherine L Ender; Margaret T Lee; Sujit Sheth; Maureen Licursi; Jennifer Crotty; Sandra Barral; Nancy S Green
Journal:  J Pediatr Hematol Oncol       Date:  2011-10       Impact factor: 1.289

2.  GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

Authors:  Jungshan Chang; John T Patton; Arun Sarkar; Beat Ernst; John L Magnani; Paul S Frenette
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

3.  MALDI-TOF MS in Prenatal Genomics.

Authors:  Xiao Yan Zhong; Wolfgang Holzgreve
Journal:  Transfus Med Hemother       Date:  2009-06-25       Impact factor: 3.747

Review 4.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

5.  Alpha thalassemia, but not βS-globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort.

Authors:  Betânia Lucena Domingues Hatzlhofer; Diego Antonio Pereira-Martins; Igor de Farias Domingos; Gabriela da Silva Arcanjo; Isabel Weinhäuser; Diego Arruda Falcão; Isabela Cristina Cordeiro Farias; Jéssica Vitória Gadelha de Freitas Batista; Luana Priscilla Laranjeira Prado; Jéssica Maria Florencio Oliveira; Thais Helena Chaves Batista; Marcondes José de Vasconcelos Costa Sobreira; Rodrigo Marcionilo de Santana; Amanda Bezerra de Sá Araújo; Manuela Albuquerque de Melo; Bruna Vasconcelos de Ancântara; Juan Luiz Coelho-Silva; Ana Beatriz Lucas de Moura Rafael; Danízia Menezes de Lima Silva; Flávia Peixoto Albuquerque; Magnun Nueldo Nunes Santos; Ana Cláudia Dos Anjos; Fernando Ferreira Costa; Aderson da Silva Araújo; Antonio Roberto Lucena-Araújo; Marcos André Cavalcanti Bezerra
Journal:  Ann Hematol       Date:  2021-02-13       Impact factor: 3.673

6.  Protective BCL11A and HBS1L-MYB polymorphisms in a cohort of 102 Congolese patients suffering from sickle cell anemia.

Authors:  Tite Minga Mikobi; Prosper Tshilobo Lukusa; Michel Ntetani Aloni; Aimé Zola Lumaka; Didine Kinkodi Kaba; Koenraad Devriendt; Gert Matthijs; Jean Marie Mbuyi Muamba; Valérie Race
Journal:  J Clin Lab Anal       Date:  2017-03-23       Impact factor: 2.352

7.  Clinical phenotypes and the biological parameters of Congolese patients suffering from sickle cell anemia: A first report from Central Africa.

Authors:  Tite M Mikobi; Prosper Lukusa Tshilobo; Michel N Aloni; Pierre Z Akilimali; Georges Mvumbi-Lelo; Jean Marie Mbuyi-Muamba
Journal:  J Clin Lab Anal       Date:  2017-01-23       Impact factor: 2.352

8.  Safety and efficacy of hydroxyurea in children and adolescents with sickle/beta-thalassemia: two-year experience.

Authors:  E Papadopoulou; A Teli; S Theodoridou; N Gompakis; M Economou
Journal:  Hippokratia       Date:  2015 Apr-Jun       Impact factor: 0.471

9.  Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea.

Authors:  Françoise Bernaudin; Cécile Arnaud; Annie Kamdem; Isabelle Hau; Françoise Lelong; Ralph Epaud; Corinne Pondarré; Serge Pissard
Journal:  Blood Adv       Date:  2018-03-27

10.  Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease.

Authors:  Nm Wiles; J Howard
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.